All AChE-I VaD trials done only out to 6 months; no 18-month data. Metaanalysis influenced by a neutral CADASIL trial70 although unclear how relevant monogenic cSVD treatments might be to sporadic cSVD? Cannot be trialled in mixed dementia since many will be on an AChE-I. Unclear whether AChE-Is have any neuroprotective role.44 The gene discussed is ACHE; the disease is dementia.